Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis

Authors

Carol A. Burke, Cleveland Clinic
Paul E. Wise, Washington University School of Medicine in St. Louis
et al

Journal

The New England Journal of Medicine

Publication Date

2020

Volume

383

Issue

11

First Page

1028

Last Page

1039

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1916063

Rights and Permissions

Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Hüneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. N Engl J Med. 2020 Sep 10;383(11):1028-1039. doi: 10.1056/NEJMoa1916063 Copyright © 2020 Massachusetts Medical Society. All rights reserved. https://www.nejm.org/doi/10.1056/NEJMoa1916063?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Recommended Citation

Burke, Carol A.; Wise, Paul E.; and al, et, "Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis." The New England Journal of Medicine. 383, 11. 1028 - 1039. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/10697